Are tetanus toxoid and human tetanus immune globulin (HTIG) 250 IU (0.5 mL) supplied in a single ampule?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No, tetanus toxoid and human tetanus immune globulin (HTIG) are NOT supplied together in a single ampule

Tetanus toxoid and human tetanus immune globulin (HTIG) 250 IU must be administered as separate products, using separate syringes and separate injection sites. This is a critical safety and efficacy requirement that is consistently emphasized across all guidelines and drug labeling.

Key Administration Requirements

Separate Products, Separate Sites

When both tetanus toxoid (or Td/Tdap) and TIG are indicated for wound management:

  • TIG dose: 250 units intramuscularly 1
  • Tetanus toxoid dose: 0.5 mL intramuscularly 2
  • Administration: Must use separate syringes and separate anatomic sites 1
  • Toxoid type: Adsorbed toxoid is mandatory when given concurrently with TIG 1

Why Separate Administration Matters

The requirement for separate sites prevents potential interference between passive and active immunization. While adsorbed tetanus toxoid given simultaneously with human TIG shows minimal to no interference with the immune response 3, 4, 5, maintaining separate injection sites remains the standard of care to ensure optimal protection from both passive antibodies and active immunization 1.

Product Formulations

Tetanus Toxoid Products

  • Available as 0.5 mL single-dose preparations 6
  • Formulated as Td (adult) or DT/DTaP (pediatric) 2
  • Each 0.5 mL dose contains 2-10 Lf units of tetanus toxoid depending on formulation 7

Human Tetanus Immune Globulin

  • Supplied separately as 250 IU dose 1
  • Administered intramuscularly at a different site than toxoid 8

Clinical Pitfall to Avoid

Never assume these products come combined. The question likely arises from confusion about the simultaneous administration recommendation. While both products may be given during the same clinical encounter for tetanus-prone wounds in inadequately immunized patients, they remain distinct pharmaceutical preparations that must be drawn up separately and injected at different anatomic sites 1, 8.

Human TIG provides immediate passive protection while the toxoid initiates active immunity—but this dual protection requires proper separate administration to be effective 9, 5.

References

Research

Active immunization against tetanus in man. II. Combined active and passive prophylaxis with human tetanus immune globulin.

Zeitschrift fur Immunitatsforschung, experimentelle und klinische Immunologie, 1976

Research

[Current trends in the use of combined serum and vaccine in tetanus prevention].

Bollettino dell'Istituto sieroterapico milanese, 1980

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.